RxDoctor Payments DataLook up a doctor →

Carol Alvarado-Barrantes, MD

Internal Medicine · Wilmington, DENPI 1740487099

Payments from drug & device makers

$9,808in general payments, 2019–2025

Across 573 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$933
  • Pfizer$875
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$701
  • Boehringer Ingelheim$675
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,63098%
  • Education$1401%
  • Entertainment$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,808 in reported general payments places this provider in the 90th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$24,092
Medicare patients
51
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$96,734
FarxigaDapagliflozin Propanediol55$78,330
XifaxanRifaximin18$61,892
RybelsusSemaglutide46$50,627
MounjaroTirzepatide34$47,950
EliquisApixaban31$38,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$36,235
XareltoRivaroxaban29$34,429
TrulicityDulaglutide13$33,807
LinzessLinaclotide34$32,661
OzempicSemaglutide32$29,876
ProliaDenosumab11$19,563
Soliqua 100-33Insulin Glargine/Lixisenatide24$19,420
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$13,352
AbrysvoRsv Vacc, Pref A And Pref B/Pf38$11,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$675$107,835110 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,186$91,68268 claims
Lilly USA, LLCMounjaro, Trulicity$933$81,75747 claims
Novo NordiskRybelsus, Ozempic$1,177$80,50478 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$701$61,89218 claims
PfizerEliquis, Abrysvo$875$50,07069 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Shingrix$177$48,73179 claims
Johnson & JohnsonXarelto$12$34,42929 claims
AbbVieLinzess$416$32,66134 claims
AmgenProlia$267$19,56311 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$234$19,42024 claims
Astellas Pharma US IncMyrbetriq$238$11,31817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →